Docoh
Loading...

TEVA Teva- Pharmaceutical Industries

Employees

Data from SEC filings
Employee count
CEO pay ratio
CEO Salary
Median Employee Salary

ESG framework mentions

In last year of SEC filings
Sustainability Accounting Standards Board (SASB)
No mentions
Global Reporting Initiative (GRI)
No mentions
Task Force on Climate-related Financial Disclosures (TCFD)
No mentions
UN Sustainable Development Goals (SDGs)
No mentions

ESG term mentions

In last year of SEC filings
AirCleanClimateClimate ActionClimate ChangeEffluentEmissionEnvironmentEnvironmentalEnvironmental ProtectionForestGHGGreenGreenhouse GasLifecycleMaterialsNatural ResourcesNatureOffsetPackagePackagingPandemicPlanetPollutantRaw MaterialsSoilSpillSuperfundWasteWaterAccessAfrican AmericanAsianBenefitsBlackCalifornia Consumer Privacy ActCharityCollective BargainingCommunityCultureCustomerCyberCyber SecurityCybersecurityData PrivacyData SecurityDeathDisabilityDiversityDrug PricingEmployeeEmployee EngagementEmployee Resource GroupEmployee TrainingEngagementEthnicityGenderGeneral Data Protection RegulationHealth and SafetyHealth CareHealthcareHireHiringHispanicHuman CapitalHuman ResourcesIncidentInjuriesInjuryLabor practiceMinorityOpioidOvertimePay for PerformancePerquisitesPrivacyProduct SafetyRecallRecruitRecruitmentReimbursementRetentionRetirementSafetySatisfactionSkillSkilledSkillsSocialSocietyStakeholderSupplierSupply ChainSustainability-linked BondTalentTrainingUnionWomenWorkforceWorking ConditionAction PlanAnti-corruptionAntitrustAssessmentAssuranceAttorney GeneralAttorneys GeneralAuditBoard EvaluationBoard OversightBoard RefreshmentBonusBriberyChronicClass Action LawsuitClassifiedClassified BoardClawbackCommitmentCommittee EvaluationControversyCorporate GovernanceCorporate PurposeCorruptionDepartment ofESGEthicsExecutive CompensationExpertFraudGoalsGovernanceHedgingIncentiveIncentivizeIndependenceIndependentInnovateInnovationInnovativeInvestigationKey Performance IndicatorLawsuitLead Independent DirectorLeadershipLitigationLong-termMajorityMaterialityMateriality AssessmentMissionOverseeOversightPerquisitePlaintiffPledgingProcurementPurposeQuality StandardR&DRecoupReputationReputationalReputational RiskResearch and DevelopmentResponsibilityResponsibleSelf-evaluationShareholder EngagementShareholder ProposalsStrategySustainabilitySustainableTargetsTaxTax Gross UpTenureTerm LimitTransparencyTransparentVoting Rights

Shareholder alignment

Proxy contests and exempt solicitations in last 3 years

No recent proxy contest or exempt solicitation filings from shareholders.

Vote support at last AGM
Teva Pharmaceutical Industries Limited (“Teva”) held its Annual Meeting on June 14, 2021 (the “Annual Meeting”). The following is a summary of the matters voted on at the meeting.

(1)The shareholders elected to appoint the following persons to the Board, to serve until Teva’s 2024 annual meeting of shareholders, as follows:


DirectorsForAgainstAbstainBrokers
non-vote
Rosemary A. Crane491,952,352145,903,4364,447,179106,682,601
Abbas Hussain500,596,337137,203,1784,503,452106,682,601
Gerald M. Lieberman496,219,634141,634,8234,448,510106,682,601
Prof. Ronit Satchi-Fainaro499,182,665138,677,2674,443,035106,682,601


(2)The shareholders approved, on a non-binding advisory basis, the compensation for Teva’s named executive officers listed in the proxy statement for the Annual Meeting, as follows:


ForAgainstAbstainBrokers non-vote
482,430,718155,538,5984,333,651106,682,601


(3)The shareholders approved the appointment of Kesselman & Kesselman, a member of PricewaterhouseCoopers International Ltd., as Teva’s independent registered public accounting firm until Teva’s 2022 annual meeting of shareholders, as follows:


ForAgainstAbstainBrokers non-vote
579,437,570162,313,4174,426,7520